Microglial cells (MGs) are resident immune cells in the brain, which play a key role in the acute response and chronic recovery to stroke. Investigators at the University of Texas Health Science Center Houston aimed to evaluate MG transcriptomic response to stroke in mouse brain.

NRG Therapeutics Ltd. has been awarded a second US$500,000 grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF), to support its lead drug discovery program and the development of a novel treatment for Parkinson's disease.

Herantis Pharma plc has received approval from the Finnish Medicines Agency, Fimea, and an ethics committee for a clinical trial application (CTA) to start clinical development of HER-096 for Parkinson's disease.

Wolfram syndrome is a neurodegenerative disease characterized by neurological symptoms, as well as diabetes, optic atrophy and hearing loss, among others. The WFS1 gene encodes a protein named Wolframin and it accounts for about 99% of cases, 60% of which present with hearing loss. To date, of all animal models of Wolfram syndrome developed carrying a variant or deletion of one exon of Wfs1, none mimics the early-onset hearing loss.